Bristol Myers pulling out of Russia, closing trials
BMS will sell products to Russia through Swixx, a third-party distributor
Bristol Myers is the first multinational pharmaceutical company to withdraw from Russia following the country’s invasion of Ukraine. It is closing clinical trials in Russia, shutting down its Russian subsidiary and shifting its commercial operations to a third party.
Although it will no longer have a footprint in Russia, Bristol Myers Squibb Co. (NYSE:BMY) will sell its products there through Swixx BioPharma AG, a Swiss distributor specializing in central and eastern Europe. ...